{"title":"A novel recombinant chimeric Fiber-8a/8b-AD subunit vaccine provides complete protection against both FAdV-8a and FAdV-8b","authors":"Xiangqin Wang , Wanzhe Yuan","doi":"10.1016/j.vetmic.2025.110425","DOIUrl":null,"url":null,"abstract":"<div><div>In recent years, outbreaks of fowl adenovirus (FAdV) in domestic chicken populations in China, particularly fowl adenovirus serotype 8 (FAdV-8), have attracted significant attention due to its role as a major causative agent of inclusion body hepatitis (IBH). Although FAdV-8 exhibits lower virulence compared to FAdV-4, its ability to co-infect with other pathogens presents new challenges for vaccine development. In this study, full-length and chimeric expression technologies were applied to develop four novel subunit vaccines using Fiber proteins from FAdV-8a and FAdV-8b strains: Fiber-8a-AB, Fiber-8b-CD, Fiber-8a/8b-AD, and Fiber-8b/8a-CB. Immunogenicity experiments indicated that the Fiber-8a/8b-AD subunit vaccine induced production of antibodies at 14 days of age earlier than the other three subunit vaccine. Moreover, the neutralizing antibody level of the Fiber-8a/8b-AD subunit vaccine group was higher than the three subunit vaccine groups. Immuno-challenge tests confirmed that this vaccine effectively protected chickens from weight loss, liver damage, and viral shedding post FAdV-8a and FAdV-8b infection. These findings valuable crucial insights for the development of new vaccines and suggest that the Fiber-8a/8b-AD subunit vaccine has the potential to serve as an effective alternative to inactivated whole-virus vaccines, with substantial commercial potential.</div></div>","PeriodicalId":23551,"journal":{"name":"Veterinary microbiology","volume":"303 ","pages":"Article 110425"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary microbiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378113525000604","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In recent years, outbreaks of fowl adenovirus (FAdV) in domestic chicken populations in China, particularly fowl adenovirus serotype 8 (FAdV-8), have attracted significant attention due to its role as a major causative agent of inclusion body hepatitis (IBH). Although FAdV-8 exhibits lower virulence compared to FAdV-4, its ability to co-infect with other pathogens presents new challenges for vaccine development. In this study, full-length and chimeric expression technologies were applied to develop four novel subunit vaccines using Fiber proteins from FAdV-8a and FAdV-8b strains: Fiber-8a-AB, Fiber-8b-CD, Fiber-8a/8b-AD, and Fiber-8b/8a-CB. Immunogenicity experiments indicated that the Fiber-8a/8b-AD subunit vaccine induced production of antibodies at 14 days of age earlier than the other three subunit vaccine. Moreover, the neutralizing antibody level of the Fiber-8a/8b-AD subunit vaccine group was higher than the three subunit vaccine groups. Immuno-challenge tests confirmed that this vaccine effectively protected chickens from weight loss, liver damage, and viral shedding post FAdV-8a and FAdV-8b infection. These findings valuable crucial insights for the development of new vaccines and suggest that the Fiber-8a/8b-AD subunit vaccine has the potential to serve as an effective alternative to inactivated whole-virus vaccines, with substantial commercial potential.
期刊介绍:
Veterinary Microbiology is concerned with microbial (bacterial, fungal, viral) diseases of domesticated vertebrate animals (livestock, companion animals, fur-bearing animals, game, poultry, fish) that supply food, other useful products or companionship. In addition, Microbial diseases of wild animals living in captivity, or as members of the feral fauna will also be considered if the infections are of interest because of their interrelation with humans (zoonoses) and/or domestic animals. Studies of antimicrobial resistance are also included, provided that the results represent a substantial advance in knowledge. Authors are strongly encouraged to read - prior to submission - the Editorials (''Scope or cope'' and ''Scope or cope II'') published previously in the journal. The Editors reserve the right to suggest submission to another journal for those papers which they feel would be more appropriate for consideration by that journal.
Original research papers of high quality and novelty on aspects of control, host response, molecular biology, pathogenesis, prevention, and treatment of microbial diseases of animals are published. Papers dealing primarily with immunology, epidemiology, molecular biology and antiviral or microbial agents will only be considered if they demonstrate a clear impact on a disease. Papers focusing solely on diagnostic techniques (such as another PCR protocol or ELISA) will not be published - focus should be on a microorganism and not on a particular technique. Papers only reporting microbial sequences, transcriptomics data, or proteomics data will not be considered unless the results represent a substantial advance in knowledge.
Drug trial papers will be considered if they have general application or significance. Papers on the identification of microorganisms will also be considered, but detailed taxonomic studies do not fall within the scope of the journal. Case reports will not be published, unless they have general application or contain novel aspects. Papers of geographically limited interest, which repeat what had been established elsewhere will not be considered. The readership of the journal is global.